ArticleDiscover oncology2025
Predictive and prognostic value of inflammatory factors (IL-6, IL-8, and TNF-α) in saliva for radiotherapy response in patients with HPV-associated oropharyngeal squamous cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combined Model of Inflammatory-Nutritional Indicators and Tumor Markers for Predicting Prognosis in Patients with Distal Cholangiocarcinoma: A Retrospective Cohort Study.Diseases (Basel, Switzerland) · 2026Article
- Obesity and Pro-Inflammatory Cytokines: Gene Expression Patterns Within Cervical Cancer Progression.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis investigation focused on analyzing saliva inflammatory factors (IL-6, IL-8, and TNF-α) to predict radiotherapy response and determine prognostic value in individuals with HPV-linked oropharyngeal squamous cell carcinoma (OPSCC).
methodsSixty patients diagnosed with HPV-associated OPSCC and treated with 3D conformal intensity-modulated radiotherapy at our hospital from June 2016 to June 2020 were selected, as well as 60 healthy individuals who underwent outpatient physical exams as the control group. The relationship between saliva IL-6, IL-8, and TNF-α and clinicopathological features was analyzed. The relationship between HPV status and radiotherapy response in OPSCC patients was analyzed, and the predictive value of saliva inflammatory factors on radiotherapy response was analyzed by ROC curves, and the factors influencing the prognosis of OPSCC were analyzed by Cox regression.
resultsSaliva IL-6, IL-8, and TNF-α in OPSCC patients did not show any statistically significant differences when analyzed across different genders, ages, tumor sites, histological grades, tumor sizes, clinical stages, cervical lymph node metastasis, and HPV status. IL-6, IL-8, and TNF-α in OPSCC patients were higher than those in healthy individuals. Patients with HPV-positive OPSCC were more sensitive to radiotherapy compared to those with HPV-negative. Saliva TNF-α levels were elevated in the radiotherapy-sensitive OPSCC patients, with IL-6 and IL-8 levels being lower than those in radiotherapy-insensitive patients. For predicting radiotherapy response, the AUC for IL-6, IL-8, and TNF-α was 0.744, 0.750, and 0.742, respectively, with the combination yielding an AUC of 0.821. Among OPSCC patients, those who survived showed higher TNF-α levels in saliva and lower IL-6 and IL-8 levels compared with those died. Elevated TNF-α level in saliva and sensitivity to radiotherapy were protective factors affecting prognosis, and elevated IL-6 and IL-8 were risk factors.
conclusionSaliva IL-6, IL-8, and TNF-α are related to radiotherapy sensitivity and prognosis in patients with HPV-associated OPSCC, which can guide the selection of clinical treatment programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.